Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9201MR)

This product GTTS-WQ9201MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9201MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4756MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ10513MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ9140MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ973MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ9564MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ11272MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ11912MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ13253MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW